The findings indicate that vericiguat may inhibit myocardial fibroblast activation and collagen synthesis via the TGF-β1/Smad pathway, thereby exerting a controlling effect on the recurrence of atrial fibrillation. Here, TGFB1 is linked to atrial fibrillation.